Nicox (LTS:0RCQ) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Nicox FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nicox's Free Cash Flow for the six months ended in Dec. 2023 was €0.00 Mil. Nicox's Revenue for the six months ended in Dec. 2023 was €-2.52 Mil. Therefore, Nicox's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Nicox's current FCF Yield % is -117.77%.

The historical rank and industry rank for Nicox's FCF Margin % or its related term are showing as below:

LTS:0RCQ' s FCF Margin % Range Over the Past 10 Years
Min: -161487.5 Med: -411.51 Max: -37.52
Current: -8223.74

During the past 13 years, the highest FCF Margin % of Nicox was -37.52%. The lowest was -161487.50%. And the median was -411.51%.

LTS:0RCQ's FCF Margin % is ranked worse than
90.69% of 1042 companies
in the Biotechnology industry
Industry Median: -139.2 vs LTS:0RCQ: -8223.74

Nicox FCF Margin % Historical Data

The historical data trend for Nicox's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox FCF Margin % Chart

Nicox Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-195.47

-37.52

-215.41

-10,927.83

Nicox Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-125.03	-448.15	604.79	-302.09	-

Competitive Comparison of Nicox's FCF Margin %

For the Biotechnology subindustry, Nicox's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nicox's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Nicox's FCF Margin % falls into.

Nicox FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Nicox's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	0	/	0.257
	=	0.00 %

Nicox's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0	/	-2.515
	=	0.00 %

Nicox FCF Margin % Related Terms

Thank you for viewing the detailed overview of Nicox's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox (LTS:0RCQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (LTS:0RCQ) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

NICXF:USA ALCOX:France NXOA:Germany

Address

2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560

Website

https://www.nicox.com

Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (LTS:0RCQ) Headlines

No Headlines